Barinthus Biotherapeutics (BRNS) Debt to Equity (2021)
Barinthus Biotherapeutics (BRNS) reported Debt to Equity of $0.0 for Q4 2021.
Barinthus Biotherapeutics (BRNS) Debt to Equity (2021) Analysis & Trends
Barinthus Biotherapeutics has reported Debt to Equity for 1 years, with the latest figure at $0.0 in Q4 2021.
- For the quarter ending Q4 2021, Debt to Equity changed N/A year-over-year to $0.0; the trailing twelve-month figure through Dec 2021 stood at $0.0 (changed N/A YoY), and the FY2021 full-year result was $0.0, changed N/A from the prior year.
- Debt to Equity for Q4 2021 stood at $0.0.
- The five-year high for Debt to Equity was $0.0 in Q4 2021, with the low at $0.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.00 |